Quarterly ResultMay 15, 2026, 04:38 PM
Citius Oncology Reports Q2 Net Loss $32.1M; Raises $21.5M Amid Going Concern
AI Summary
Citius Oncology, Inc. reported a net loss of $32.1 million for the six months ended March 31, 2026, with revenues of $5.6 million, marking its first revenue generation from LYMPHIR. The company faces substantial doubt about its ability to continue as a going concern due to a negative working capital of $29.4 million and limited cash. To address this, Citius Oncology recently secured $11.5 million from warrant exercises and an initial $10.0 million from a new $25.0 million loan facility.
Key Highlights
- Net loss for the six months ended March 31, 2026, was $32.1 million, compared to $14.4 million in the prior year.
- Revenues for the six months ended March 31, 2026, totaled $5.6 million, up from $0 in the prior year.
- Cash and cash equivalents stood at $2.6 million as of March 31, 2026.
- Company reported negative working capital of $29.4 million at March 31, 2026.
- Received $11.5 million gross proceeds from warrant exercises on May 5, 2026.
- Secured a loan agreement for up to $25.0 million, with $10.0 million funded on May 6, 2026.
- Management identified substantial doubt about the company's ability to continue as a going concern.
- Commercial launch of LYMPHIR commenced in December 2025.
Price Impact
More from CTOR